EUVIMEDEUVIMED entdecken
Crossref

The Development, Efficacy and Safety Profiles of Bispecific Antibodies for Solid Tumors: Amivantamab for EGFR-mutant NSCLC and Tebentafusp for Uveal Melanoma

Priya Hays

Archives of Microbiology & Immunology · 2026 · 10 (2)

DOI: 10.26502/ami.936500236 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Archives of Microbiology & Immunology, 2026. Verfasst von Priya Hays.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Zitieren

APA

Hays, P. (2026). The Development, Efficacy and Safety Profiles of Bispecific Antibodies for Solid Tumors: Amivantamab for EGFR-mutant NSCLC and Tebentafusp for Uveal Melanoma. Archives of Microbiology & Immunology, 10(2). https://doi.org/10.26502/ami.936500236

Vancouver

Hays P. The Development, Efficacy and Safety Profiles of Bispecific Antibodies for Solid Tumors: Amivantamab for EGFR-mutant NSCLC and Tebentafusp for Uveal Melanoma. Archives of Microbiology & Immunology. 2026;10(2). doi:10.26502/ami.936500236

BibTeX
@article{Hays2026,
  author = {Hays, Priya},
  title = {The Development, Efficacy and Safety Profiles of Bispecific Antibodies for Solid Tumors: Amivantamab for EGFR-mutant NSCLC and Tebentafusp for Uveal Melanoma},
  journal = {Archives of Microbiology & Immunology},
  year = {2026},
  volume = {10},
  number = {2},
  doi = {10.26502/ami.936500236}
}
Kostenlos starten →